TRVI | Ticker Profile - Titan Protect

TRVI

Trevi Therapeutics, Inc.

Healthcare · Biotechnology · NGM

$13.33

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.1B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-25.91

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-33.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$24.00

+80% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 10 analysts covering this stock

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.

https://www.trevitherapeutics.com

Country: United States Employees: 34 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

1.509

Excellent risk-adjusted returns

Kelly Fraction

0.0986

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

4.738

Returns exceed worst-case losses — strong risk profile

Annual Return

139.8%

Historical annualised return based on price data

Max Drawdown

-29.5%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

159

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.08

Moves slightly more than the broader market

52W High

$16.12

17% below the year high

52W Low

$5.38

148% above the year low

Avg Volume

1,522,801

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

10.4%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.32

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.40

Conservative use of debt — low financial risk

Current Ratio

24.75

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

24.30

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-28,527,250

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-45,611,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$30.00

Target Median

$24.00

Target Low

$20.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go